N※N

AVEO Pharmaceuticals, Inc. to Present at Several Upcoming Investment Conferences

  //health-fitness.news-articles.net/content/2010/ .. -at-several-upcoming-investment-conferences.html
  Published in Health and Fitness on Thursday, September 2nd 2010 at 6:36 GMT by Market Wire
          ^{🞛 This publication is a summary or evaluation of another publication}

CAMBRIDGE, Mass.--([ BUSINESS WIRE ])--AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that the companya™s management will present at several upcoming investment conferences.

Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the following events:

• Morgan Stanley Global Healthcare Conference on Monday, September 13, 2010 at 3:55 p.m. (EDT) at the Grand Hyatt in New York City.
• UBS Global Life Sciences Conference on Monday, September 20, 2010 at 10:00 a.m. (EDT) at the Grand Hyatt in New York City.

David Johnston, chief financial officer, is scheduled to present at the following event:

• JMP Securities Fifth Annual Healthcare Conference on Monday, September 27, 2010 at 3:30 p.m. (EDT) at the Palace Hotel in New York City.

AVEOa™s presentations will be webcast live and can be accessed by visiting the investors section of the companya™s website at [ www.investor.aveopharma.com ]. A replay of the webcasts will be archived on the AVEO website for two weeks following each presentation date, respectively.

About AVEO

AVEO Pharmaceuticals (NASDAQ: AVEO) integrates a proprietary cancer biology platform with drug development and commercial expertise in its efforts to discover and develop targeted cancer therapeutics. The companya™s lead product, tivozanib, is an oral, triple VEGF receptor inhibitor with a highly differentiated profile. Tivozanib is currently being investigated in a global, randomized Phase 3 clinical trial called TIVO-1 comparing tivozanib to sorafenib in advanced kidney cancer, as well as additional clinical studies in other solid tumor types. AVEOa™s proprietary, integrated cancer biology platform offers the company a unique advantage in oncology drug development and has provided a discovery engine for high-value targets. This approach has resulted in a promising pipeline of monoclonal antibodies against novel targets includingHGF, ErbB3, RON, Notch andFGFR. For more information, please visit the company's website at [ www.aveopharma.com ].